Genocea Provides Third Quarter 2020 Corporate Update
Genocea Biosciences (NASDAQ: GNCA) announced the initiation of its GEN-011 Phase 1/2a clinical trial, following FDA approval of its IND application. The trial will evaluate safety and clinical activity in patients who have previously failed standard therapies, enrolling up to 24 participants. The company also reported promising follow-up data from its GEN-009 trial, showing tumor reductions or stable outcomes in all patients presented. With a cash position of $87.6 million as of September 30, 2020, Genocea is well-funded to advance its clinical programs through mid-2022.
- Initiated GEN-011 Phase 1/2a clinical trial, targeting patients who failed prior therapies.
- Presented positive follow-up data for GEN-009, showing tumor reductions in all five patients.
- Cash position improved to $87.6 million, sufficient to fund operations to mid-2022.
- Continued net loss of $4.6 million for Q3 2020, though reduced from $7.5 million in Q3 2019.
- R&D expenses increased to $7.5 million, indicating rising operational costs.
Initiated GEN-011 Phase1/2a clinical trial
Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy
Closed financing with net proceeds of
Upcoming presentations at SITC 2020 Virtual Conference on GEN-009, InhibigensTM and GEN-011
Conference call today at 8:30 a.m. EDT
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today reported its operating and financial results for the third quarter ended September 30, 2020.
GEN-011 Phase 1/2a clinical trial initiation
Genocea recently announced the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) Application for GEN-011, an adoptive neoantigen T cell therapy designed to improve upon the limitations of TIL and TCR therapies. The company initiated a Phase 1/2a clinical study of GEN-011 in patients who have failed standard-of-care checkpoint inhibitor therapy to evaluate safety, T cell proliferation and persistence as well as clinical activity. Genocea plans to enroll up to 24 patients across several tumor types in the trial.
Scientific and clinical presentations: ESMO Congress, upcoming SITC meeting and conference call
Genocea presented clinical response and immunogenicity data on the first five patients from Part B of the ongoing GEN-009 Phase 1/2a trial at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The incremental follow-up findings demonstrated tumor reductions or stable outcomes for all five patients, suggesting GEN-009 vaccination could be used in conjunction with CPI-based therapies to augment their effects. In addition,
Genocea will report additional clinical and immunogenicity data from the remaining GEN-009 Part B patients during the 2020 virtual Society for Immunotherapy of Cancer (SITC) annual meeting from November 9-14. The company will also provide a detailed introduction to GEN-011 and will share new insights on the utility of ATLAS-identified Inhibigens to inform future immunotherapy development.
Genocea will host a conference call on Monday, November 9 at 8:30 a.m. EST to discuss the new GEN-009 clinical and immunogenicity data reported at SITC.
Private placement
In July, Genocea completed a private placement with
"In the third quarter, our team achieved important clinical, scientific and financial progress. We provided what we believe to be differentiated immunogenicity and efficacy data from an initial look at our GEN-009 Part B clinical trial and secured critical fresh capital", said Chip Clark, president and chief executive officer Genocea. "Using these proceeds to advance GEN-011 into the clinic and to further our investigation into ATLAS and its applications represents an exciting opportunity."
Third Quarter 2020 Financial Results
- Cash position: As of September 30, 2020, cash and cash equivalents were
$87.6 million versus$40.1 million as of December 31, 2019. - Research and Development (R&D) expenses: R&D expenses were
$7.5 million for the quarter ended September 30, 2020, compared to$6.8 million for the same period in 2019. - General and Administrative (G&A) expenses: G&A expenses were
$3.6 million for the quarter ended September 30, 2020, compared to$2.8 million for the same period in 2019. - Net loss: Net loss was
$4.6 million for the quarter ended September 30, 2020, compared to$7.5 million for the same period in 2019.
Guidance
Genocea expects that its existing cash and cash equivalents are sufficient to support its operations to mid-2022.
Conference Call
Genocea will host a conference call and webcast today at 8:30 a.m. EDT. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5951388. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations. A webcast replay of the conference call will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.
About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood for which we are commencing a Phase 1/2a clinical trial. To learn more, please visit www.genocea.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.
Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com
(Tables to follow)
GENOCEA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands)
| September 30, 2020 | December 31, 2019 | |||||||
| Cash and cash equivalents | $ | 87,625 | $ | 40,127 | ||||
| Right of use assets | 10,737 | 6,306 | ||||||
| Other assets | 7,836 | 6,178 | ||||||
| Total assets | $ | 106,198 | $ | 52,611 | ||||
| Accounts payable and accrued expenses | $ | 6,351 | $ | 5,164 | ||||
| Deferred revenue | 1,641 | — | ||||||
| Debt, current and long-term | 13,743 | 13,407 | ||||||
| Warrant liabilities | 53,237 | 2,486 | ||||||
| Lease liabilities | 11,021 | 6,512 | ||||||
| Total liabilities | 85,993 | 27,569 | ||||||
| Stockholders' equity | 20,205 | 25,042 | ||||||
| Total liabilities and stockholders’ equity | $ | 106,198 | $ | 52,611 | ||||
GENOCEA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| License revenue | $ | 453 | $ | — | $ | 1,359 | $ | — | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 7,548 | 6,826 | 26,123 | 20,135 | |||||||||||
| General and administrative | 3,644 | 2,758 | 10,511 | 8,992 | |||||||||||
| Total operating expenses | 11,192 | 9,584 | 36,634 | 29,127 | |||||||||||
| Loss from operations | (10,739 | ) | (9,584 | ) | (35,275 | ) | (29,127 | ) | |||||||
| Other income (expense) | 6,184 | 2,052 | 6,546 | (467 | ) | ||||||||||
| Net loss | $ | (4,555 | ) | $ | (7,532 | ) | $ | (28,729 | ) | $ | (29,594 | ) | |||
| Net loss per share: | |||||||||||||||
| Basic | $ | (0.08 | ) | $ | (0.28 | ) | $ | (0.76 | ) | $ | (1.62 | ) | |||
| Diluted | $ | (0.26 | ) | $ | (0.28 | ) | $ | (1.01 | ) | $ | (1.62 | ) | |||
| Weighted-average number of shares used in computing net loss per share: | |||||||||||||||
| Basic | 55,492 | 26,681 | 37,657 | 18,297 | |||||||||||
| Diluted | 61,130 | 26,681 | 39,550 | 18,297 | |||||||||||
FAQ
What is the focus of the GEN-011 Phase 1/2a clinical trial by GNCA?
What were the latest financial results reported by Genocea for Q3 2020?
How much cash does Genocea have as of September 30, 2020?
What positive data was presented by Genocea at the ESMO Virtual Congress 2020?
When will Genocea host a conference call to discuss its latest data?
